Xencor, Inc. - Common Stock (XNCR)
Frequently Asked Questions About Xencor, Inc. - Common Stock (XNCR)
How can investors stay updated on Xencor, Inc.?
Investors can stay updated on Xencor, Inc. by following the company’s official website, subscribing to press releases, and monitoring financial news platforms for coverage on company developments. The company also holds quarterly earnings calls and annual shareholder meetings where updates on its operations and financial performance are discussed.
How does Xencor collaborate with other companies?
Xencor actively engages in collaborations and partnerships with other pharmaceutical and biotechnology companies to enhance its research and development capabilities. These collaborations often involve licensing agreements, joint ventures, and co-development initiatives, allowing Xencor to expand its pipeline and leverage complementary technologies and expertise.
Is Xencor, Inc. involved in any clinical trials?
Yes, Xencor is actively involved in several clinical trials for its drug candidates. The company conducts Phase 1 and Phase 2 studies to evaluate the safety, tolerability, and efficacy of its innovative therapeutics in patients with specific types of cancer and autoimmune diseases, providing critical data to inform the next steps in drug development.
What are some of the pipeline candidates of Xencor, Inc.?
Xencor's pipeline includes several promising drug candidates, such as XmAb®20717, a bispecific antibody designed to engage both CD3 and PD-1, and XmAb®23104, targeting autoimmune diseases. These candidates are in various stages of preclinical and clinical development, showcasing the company's focus on innovative therapies with potential for significant clinical impact.
What are the key financials for Xencor, Inc.?
Xencor's financials consist of revenue generated primarily through collaborations, research grants, and the advancement of clinical candidates. Investors typically look at key metrics such as revenue growth, research and development expenditures, and net losses, which indicate the company's investment in its promising pipeline and potential future value.
What are the risks associated with investing in Xencor, Inc.?
Investing in Xencor, Inc. involves certain risks typical of biotechnology firms, including the uncertainty of clinical trial results, regulatory approvals, and the overall market dynamics affecting drug development. Additionally, factors such as competition, funding needs, and market acceptance of their therapies may impact the company’s future performance and stock price.
What does Xencor, Inc. do?
Xencor, Inc. is a biopharmaceutical company focused on creating differentiated monoclonal antibodies for the treatment of cancer and autoimmune diseases. Their proprietary XmAb® technology platform enables the development of drugs with enhanced efficacy and safety profiles, which are designed to improve patient outcomes. The company is actively advancing its proprietary pipeline of therapeutic candidates through clinical trials aimed at targeting specific disease pathways.
What is the market performance of Xencor, Inc. stock?
Xencor, Inc.'s stock performance varies based on market conditions, clinical trial results, and company announcements. Investors and analysts often monitor the stock price and trading volume, alongside broader market trends in the biotech sector, to gauge the company's current market position and investor sentiment.
What is the XmAb® technology platform?
The XmAb® technology platform is a proprietary antibody engineering technology developed by Xencor. It enables the design of monoclonal antibodies with enhanced properties, such as improved stability, extended half-life, and the ability to engage immune effector cells. This platform underpins Xencor's development of both antibody-drug conjugates and bispecific antibodies aimed at treating various forms of cancer and autoimmune diseases.
What is Xencor's approach to drug discovery?
Xencor employs a systematic approach to drug discovery leveraging its advanced XmAb® technology platform, along with rigorous preclinical and clinical testing. The company focuses on targeting specific mechanisms of disease and utilizes extensive biochemistry and antibody engineering techniques to develop medicines that are not only effective but also safe for patients.
What is Xencor's strategy for growth?
Xencor's strategy for growth involves leveraging its XmAb® technology platform to expand its pipeline of therapeutic candidates while pursuing strategic collaborations and partnerships. The company aims to advance clinical programs efficiently and effectively into later stages of development, ultimately bringing novel therapies to market for patients with critical medical needs.
What is Xencor, Inc.'s mission?
Xencor's mission is to improve patient outcomes through the development of innovative monoclonal antibodies that provide more effective and safer treatment options. The company is dedicated to advancing its proprietary drug candidates and ensuring that every therapeutic target meets the highest standards for safety and efficacy.
What recent developments has Xencor announced?
Xencor regularly announces updates regarding its clinical trials, new partnerships, and advancements in its drug pipeline. Recent developments may include positive clinical trial results, new collaborations with other biotech firms, or the initiation of new studies to assess the efficacy and safety of its therapeutic candidates.
What regulatory approvals has Xencor received?
Xencor is in the process of obtaining regulatory approvals for its clinical candidates from health authorities such as the U.S. Food and Drug Administration (FDA). As part of the clinical trial process, the company submits data regarding the safety and efficacy of its drugs to seek approval for entry into the market.
What therapeutic areas does Xencor, Inc. focus on?
Xencor primarily focuses on developing therapies for cancer and autoimmune diseases. Its research is aimed at addressing significant unmet medical needs in these areas, with candidates in various stages of clinical development targeting multiple cancer types and autoimmune disorders.
When did Xencor, Inc. go public?
Xencor, Inc. went public in 2014, when it completed its initial public offering (IPO) on the Nasdaq under the ticker symbol 'XNCR'. The IPO allowed the company to raise capital to further its research and development efforts, expanding its pipeline of drug candidates.
Where is Xencor, Inc. headquartered?
Xencor, Inc. is headquartered in Monrovia, California. The location allows the company to be at the heart of the biotechnology sector, providing access to a rich network of research institutes and industry collaboration opportunities, which are essential for innovative drug development.
Who are the competitors of Xencor, Inc.?
Xencor competes with other biopharmaceutical companies that focus on similar therapeutic areas, including companies developing monoclonal antibodies and bispecific therapies. Notable competitors may include larger pharmaceutical firms and innovative biotech companies that are also advancing cutting-edge cancer therapies and treatments for autoimmune diseases.
Who is the management team at Xencor, Inc.?
Xencor's management team comprises experienced professionals with backgrounds in biotechnology, pharmaceutical development, and business management. The team is led by executives with significant expertise in drug discovery and development, helping to guide the company's strategic vision and operational direction.
What is the current price of Xencor, Inc. - Common Stock?
The current price of Xencor, Inc. - Common Stock is 8.570
When was Xencor, Inc. - Common Stock last traded?
The last trade of Xencor, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Xencor, Inc. - Common Stock?
The market capitalization of Xencor, Inc. - Common Stock is 513.55M
How many shares of Xencor, Inc. - Common Stock are outstanding?
Xencor, Inc. - Common Stock has 59.92M shares outstanding.